md-medicaldata

Authors

 

Zorana Milinković¹, Zoran Milić¹ , Nebojša Mirić¹, Jovana Baljak^1,2 , Stefan Ivić ^1,2, Tanja Lakić<sup>1,2

1</sup>Medicinski fakultet, Univerzitet u Novom Sadu
²Centar za patologiju i histologiju, Univerzitetsko klinički centar Vojvodine

 

UDK: 616.61-006.6

The paper was received / Rad primljen: 01.10.2024.

Accepted / Rad prihvaćen: 23.11.2024.

 

Correspondence to:

Zorana Milinković
Univerzitet u Novom Sadu, Medicinski fakultet Novi Sad, Srbija
Hajduk Veljkova 3, 21000, Novi Sad
e-mail: milinkoviczorana5@gmail.com

 

 

Sažetak

 

 

Uvod: Tumori bubrega mogu da budu benigni i maligni, pri čemu su maligni tumori mnogo klinički značajniji. Svetloćelijski karcinom bubrega predstavlja 2% do 3% svih malignih neoplazmi, javljaju se u 6. ili 7. deceniji. Cilj: Analiza morfoloških parametara svetloćelijskog tumora bubrega uz prikaz patohistoloških karakteristika i pratećih prognostičko-prediktivnih parametara i njihove međusobne povezanosti. Materijal i metode: Retrospektivno, izvršena je analiza medicinske dokumentacije pacijenta kojima je u petogodišnjem periodu 2018-2022. godine  u Centru za patologiju i histologiju Univerzitetskog Kliničkog centra Vojvodine patohistološki postavljena dijagnoza svetloćelijskog karcinoma bubrega. Rezultati: Patohistološki verifikovano je 240 uzoraka svetloćelijskog karcinoma bubrega, koji se češće se javlja u muškoj populaciji (142 pacijenata tj. 59,1%). Prosečna starost obolevanja ženske populacije iznosila je 61,2, a muške populacije 62,1 godina. Najčešće korišćena hirurška procedura bila je radikalna nefrektomija. Posmatrajući stranu na kojoj se nalazi tumorom zahvaćeni bubreg, u posmatranom uzorku primarni tumori su se češće javljali u desnom bubregu. Najveći dijametar tumora je iznosio 22 cm, a najmanji 1,3 cm. Zaključak: Analizom podataka o svetloćelijskom karcinomu bubrega potvrđena je veća učestalost kod muškaraca i prosečna starost pacijenata u šestoj i sedmoj deceniji života. Radikalna nefrektomija ostaje standardna hirurška metoda, dok varijacije u veličini tumora i TNM stadijumu ukazuju na potrebu za dodatnim istraživanjima. Različiti histološki gradusi i prisustvo negativnih prognostičkih faktora naglašavaju značaj individualizovanog pristupa u lečenju.

 

Ključne reči:

morfološke karakteristike, svetloćelijski karcinom bubrega, TNM klasifikacija

 

 

 

Abstract

 

Introduction: Kidney tumors can be benign and malignant, with malignant tumors being much more clinically significant. Clear cell carcinoma of the kidney represents 2% to 3% of all malignant neoplasms, usually occurring in the 6th or 7th decade. Objective: Analysis of morphological parameters of clear cell tumor of the kidney with presentation of pathohistological characteristics and accompanying prognostic-predictive parameters and their interrelationship. Material and methods: Retrospectively, we analyzed the medical records of patients who were pathohistologically diagnosed with clear cell carcinoma of the kidney from 2018 to 2022 at the Center for Pathology and Histology of the Clinical Center of Vojvodina. Results: Pathohistologically 240 samples of clear cell carcinoma of the kidney were registered, more commonly affected the male population (142 patients, i.e. 59.1%). The average female age was 61.2, and the average male age 62.1 years. The most common used surgical procedure was radical nephrectomy. Primary tumors occurred more often in the right kidney with the largest tumor diameter of 22 cm and the smallest 1.3 cm. Conclusion: Based on the analysis of data on clear cell kidney cancer, a higher incidence in men and an average patient age in the sixth and seventh decades of life have been confirmed. Radical nephrectomy remains the standard surgical method, while variations in tumor size and TNM stage highlight the need for further research. Different histological grades and the presence of negative prognostic factors emphasize the importance of an individualized approach to treatment.

 

Key words:

morphological characteristics, clear cell renal carcinoma, TNM classification

 

 

 

 

References:

1. Klącz J, Matuszewski M, Michajłowski J, Zachalski W, Markuszewski M, Krajka K. There is no place for targeted therapy neoadjuvant treatment in Polish Health System - An analysis of radical nephrectomies in patients with large kidney tumors. Cent European J Urol. 2013;66(1):31-5. doi: 10.5173/ceju.2013.01.art9.
2. Kumar V, Abbas AK, Fausto N. and Mitchell RN. (2007) Robbins Basic Pathology. 8th Edition, Saunders Elsevier, Philadelphia.
3. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010 May;7(5):245-57. doi: 10.1038/nrurol.2010.46.
4. Gkolfinopoulos S, Psyrri A, Bamias A. Clear-cell renal cell carcinoma – A comprehensive review of agents used in the contemporary management of advanced/metastatic disease. Oncol Rev. 202;15(1):530. doi: 10.4081/oncol.2021.530.
5. Thaib PKP, Rahaju AS. Clinicopathological profile of clear cell renal cell carcinoma. Int. J Health Med Sci. (Lond.) 2022;5(1):91-100.
6. Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Klatte T, Kuusk T, Lam TB, Marconi L, Powles T, Tahbaz R, Volpe A, Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006.
7. Mateljan I. Patohistološke karakteristike svijetlostaničnog i papilarnog karcinoma bubrega u pacijenata liječenih u KBC-u Split u razdoblju 2002. - 2011. godine. Diplomski rad. Split: Medicinski fakultet; 2015.
8. Zhou M, Netto M, Epstein J. Uropathology. 3rd ed. Philadelphia: Elsevier Inc; 2012.Williamson SR1, Eble JN, Cheng L, Grignon DJ. Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. ModPathol. 2013;26(5):697-708.
9. Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun. 2022;33:100640. doi: 10.1016/j.ctarc.2022.100640.
10. Bedke J, Heide J, Ribback S, Rausch S, de Martino M, Scharpf M, et al. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. BJU Int. 2018;121(1):84-92.
11. Przybycin CG, McKenney JK, Reynolds JP, Campbell S, Zhou M, Karafa MT, et al. Rhabdoid differentiation is associated with aggressive behavior in renal cell carcinoma: a clinicopathologic analysis of 76 cases with clinical follow-up. Am J Surg Pathol. 2014;38(9):1260-5.s
    

PDF: 06 - Milinković Z. et al MD-Medical Data 2024;16(3) 161-164.pdf